Topics
High-grade gliomas | Treatment | Side-effects | Hemorrhage
Home > Publications > Topics > High-grade gliomas > Treatment > Side-effects > Hemorrhage
Lim S, Clarke NH, Maloney SL, Sener UT, Caron SJ, Kizilbash SH,
Campian JL, Neth BJ, Carabenciov ID, Uhm J, Ruff MW.
Bevacizumab
exerts dose-dependent risk for
intracranial hemorrhage in patients with malignant gliomas.
J
Neurooncol. 2025 Jan 2. doi:
10.1007/s11060-024-04916-8. PMID:
39747716. Observational study˰
ˍ